# Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

> **NCT03549351** · — · TERMINATED · sponsor: **University Hospital Heidelberg** · enrollment: 51 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **OTHER:** Measurable residual disease measured by flow cytometry

## Key facts

- **NCT ID:** NCT03549351
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-01
- **Primary completion:** 2022-09-11
- **Final completion:** 2022-09-11
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** Study turned out no longer feasible
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03549351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03549351, "Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03549351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*